Skip to main content

Table 2 Clinical symptoms of mixed connective tissue disease patients with and without cardiovascular diseases

From: Endothelial cell markers reflecting endothelial cell dysfunction in patients with mixed connective tissue disease

MCTD manifestation MCTD (n = 50) MCTD/CVD+ (n = 23) MCTD/CVD- (n = 27) Pvaluea, CVD+ vs. CVD-
Disease duration (years) 9.56 ± 6.8 (3 to 26) 10.3 ± 6.6 (3 to 26) 8.9 ± 6.9 (3 to 25) 0.481
Polyarthritis 46 (92) 22 (95.6) 24 (88.8) 0.6123
Raynaud's phenomenon 39 (78) 22 (95.6) 17 (62.9) 0.006
Myositis 30 (60) 13 (56.5) 17 (62.9) 0.8621
Interstitial lung disease 40 (80) 19 (82.6) 21 (77.7) 0.7356
Photosensitivity 12 (24) 7 (30.4) 5 (18.5) 0.5077
Esophageal dysmotility 35 (70) 15 (65.2) 20 (74.0) 0.5480
Pulmonary arterial hypertension 12 (24) 9 (39.1) 3 (11.1) 0.0141
Lymphadenomegaly 13 (0.26) 5 (21.7) 8 (29.6) 0.7474
Serositis 19 (38) 11 (47.8) 8 (29.6) 0.2465
Secondary antiphospholipid syndrome 15 (30) 11 (47.8) 4 (14.8) 0.015
Previous venous thrombosis 13 (26.0) 9 (39.1) 4 (14.8) 0.618
Previous arterial occlusion 2 (4.0) 2 (8.69) 0  
Anti-U1RNP (normal: <10 U/ml) 50 (100) 23 (100) 27 (100)  
Anti-CL IgG/IgM (normal: <10 U/ml) 19 (38) 13 (56) 6 (22) 0.0195
AECA (normal: <5 U/ml) 22 (44) 15 (65) 7 (26) 0.001
SLAM (median) 5 5 4  
SLAM (mean ± SD) 6.28 ± 4.04 6.95 ± 4.08 5.44 ± 4.0 0.199
SLAM (n) 18 (36) 11 (47.8) 7 (25.9) 0.1438
Medication     
   Nonsteroidal anti-inflammatory drugs 22 (44) 10 (43.4) 12 (44.4) 1.0
Last 2 months average dose of corticosteroids (mg/day) 3.36 ± 4.8 4.1 ± 3.4 3.1 ± 5.2 0.5306
Cumulative lifetime dose (prednisone equivalent) 14.21 (4 to 58.965) 13.0 (4 to 59.432) 15.2 (4 to 57.437) 0.674
Corticosteroids alone or combination (n) 28 (56) 11 (47.8) 17 (62.9) 0.3926
Patients currently corticosteroids alone n (%) 7 (14) 2 (8.6) 5 (18.5) 0.4295
Patients currently corticosteroids plus salazopyrine 10 (20) 5 (21.7) 5 (18.5) 1.0
Patients currently corticosteroids plus methotrexate 11 (22) 5 (21.7) 6 (22.2) 1.00
   Cyclophosphamide treatment ever 37 (74) 21 (91.3) 16 (59.2) 0.0119
   Antimalaric drugs treatment ever 39 (78) 19 (82.6) 20 (74.0) 0.515
   Cyclosporin-A treatment ever 10 (20) 7 (30.4) 3 (11.1) 0.4804
  1. Data presented as mean ± standard deviation, n (%) or median (25th to 75th percentile). AECA, anti-endothelial cell antibody; anti-CL, anti-cardiolipin; anti-U1RNP, anti-U1 ribonucleoprotein; CVD, cardiovascular disease; MCTD, mixed connective tissue disease. The systemic lupus erythematosus disease activity measure (SLAM) is a measure of disease activity [24, 25]. aFischer's exact test and Student t test.
\